Literature DB >> 2671914

Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease.

S L Leikin1, D Gallagher, T R Kinney, D Sloane, P Klug, W Rida.   

Abstract

A study of the natural history of sickle hemoglobinopathies was begun in March 1979. By August 1987, a total of 2824 patients less than 20 years of age were enrolled. There have been 14,670 person-years of follow-up. Seventy-three deaths have occurred. Most of the deaths were in patients with hemoglobin SS. The peak incidence of death was between 1 and 3 years of age, and the major cause in these young patients was infection. Cerebrovascular accidents and traumatic events exceeded infections as a cause of death in patients greater than 10 years of age. There was limited success in identifying risk factors for death. Comparison of this study's overall mortality of 2.6% (0.5 deaths per 100 person-years) with previous reports indicates improvement of survival in US patients less than 20 years of age with sickle hemoglobinopathies. This improvement is most likely due to parental education and counseling about the illness and the early institution of antibiotics in suspected infections.

Entities:  

Mesh:

Year:  1989        PMID: 2671914

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  84 in total

1.  Local incentive spirometry improves peak expiratory flow rate in teenage sickle cell anaemia patients: a randomized pilot trial.

Authors:  A F Adeniyi; K S Saminu
Journal:  Afr Health Sci       Date:  2011-09       Impact factor: 0.927

Review 2.  Hydroxyurea for children with sickle cell disease.

Authors:  Matthew M Heeney; Russell E Ware
Journal:  Hematol Oncol Clin North Am       Date:  2010-02       Impact factor: 3.722

3.  Complications of sickle cell anaemia in children in Northwestern Tanzania.

Authors:  Hamza Saidi; Luke R Smart; Erasmus Kamugisha; Emmanuela E Ambrose; Deogratias Soka; Robert N Peck; Julie Makani
Journal:  Hematology       Date:  2016-02-17       Impact factor: 2.269

4.  Moderate chronic pain, weight and dietary intake in African-American adult patients with sickle cell disease.

Authors:  Jennifer J Pells; Katherine E Presnell; Christopher L Edwards; Mary Wood; Myleme O Harrison; Laura DeCastro; Stephanie Johnson; Miriam Feliu; Stephanie Canada; Jude C Jonassaint; Camela Barker; Brittani Leach-Beale; Markece J Mathis; Katherine Applegate; Anita Holmes; Goldie Byrd; Elwood Robinson
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

Review 5.  Sickle cell diseases: current therapeutic options and potential pitfalls in preventive therapy for transcranial Doppler abnormalities.

Authors:  Sharada A Sarnaik
Journal:  Pediatr Radiol       Date:  2005-02-10

6.  Genetic complexity in sickle cell disease.

Authors:  Douglas R Higgs; William G Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-11       Impact factor: 11.205

Review 7.  From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group.

Authors:  M J Khoury
Journal:  Am J Public Health       Date:  1996-12       Impact factor: 9.308

8.  Outcomes of febrile events in pediatric patients with sickle cell anemia.

Authors:  Krishnaveni Sirigaddi; Inmaculada Aban; Amelia Jantz; Brandi M Pernell; Lee M Hilliard; Smita Bhatia; Jeffrey D Lebensburger
Journal:  Pediatr Blood Cancer       Date:  2018-08-01       Impact factor: 3.167

9.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

10.  Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment.

Authors:  Melissa J Frei-Jones; Amy L Baxter; Zora R Rogers; George R Buchanan
Journal:  J Pediatr       Date:  2007-10-24       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.